Clinical trial
Prospective Evaluation of a Proteomic Signature Developed to Identify Patients Likely to Benefit From Erlotinib (TarcevaTM), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Used in the Treatment of Non-small Cell Lung Cancer
NCT01721252 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Evaluation of a Proteomic Signature Developed to Identify Patients Likely to Benefit From Erlotinib (TarcevaTM), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Used in the Treatment of Non-small Cell Lung Cancer
- Lead sponsor
- Cancer Trials Ireland
- Phase
- Observational
- Overall status
- Completed
- Start date
- December 31, 2009
- Completion date
- Not reported
- Enrollment
- 200 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
non-small cell lung cancer